Meta-analysis of 21 RCTs (9165 patients) with HR-positive/ERBB2-negative metastatic breast cancer after CDK4/6 inhibitors: no significant difference between investigator- and blinded central review-assessed PFS (discrepancy index 1.02, 95% CI 0.95-1.10).
Meta-analysisn = 9,165
Ravani et al. Progression-Free Survival in Metastatic Breast Cancer by Local Investigators vs Blinded Independent Central Review: A Systematic Review and Meta-Analysis